Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 40083242.
- Also identified by DOI 10.1002/art.43154 and PMC identifier 12311257.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high-resolution peripheral quantitative computed tomography (HR-pQCT). This was a phase 4, double-blind, randomized, placebo-controlled trial. Patients with active PsA and ≥1 erosion in metacarpophalangeal joints (MCPJs) 2 to 4 were randomly assigned in a 1:1 ratio to subcutaneous secukinumab or placebo. HR-pQCT of MCPJs 2 to 4 were performed at baseline, week 24, and week 48. The primary outcome was the changes in the volume of erosions on MCPJs 2 to 4 measured by HR-pQCT at 24 and 48 weeks. Forty patients (mean ± SD age 51.9 ± 13.4 years, 20 [50%] male, mean ± SD disease duration 4.7 ± 6.7 years) were recruited. Thirty-four patients who completed study treatment were included in the per-protocol analysis. At baseline, week 24, and week 48, the secukinumab group showed a significant reduction in erosion volume, whereas no changes were observed in the placebo group (median change in the secukinumab group -0.1 [interquartile range -0.5 to 0.0] vs 0.0 [interquartile range -0.2 to 0.4] in the placebo group, P = 0.004). A similar trend was observed for enthesiophyte volume changes in the secukinumab group, whereas no differences were noted in the placebo group (median change in the secukinumab group -0.1 [interquartile range -0.8 to 0.0] vs 0.0 [interquartile range -0.4 to 1.3] in the placebo group, P = 0.067). Generalized estimating equations results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% confidence interval [CI] 0.080-0.878, P = 0.030), whereas the OR for partial erosion healing in the secukinumab group was 2.882 (95% CI 1.130-7.349, P = 0.027). Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.
Medical subject headings
- Arthritis, Psoriatic
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Metacarpophalangeal Joint